CEB-Centre of Biological Engineering, University of Minho, Braga, Portugal.
Laboratory of Gene Technology, KU Leuven, Leuven, Belgium.
J Virol. 2019 Feb 5;93(4). doi: 10.1128/JVI.01163-18. Print 2019 Feb 15.
is an important pathogen causative of health care-associated infections and is able to rapidly develop resistance to all known antibiotics, including colistin. As an alternative therapeutic agent, we have isolated a novel myovirus (vB_AbaM_B9) which specifically infects and makes lysis from without in strains of the K45 and K30 capsule types, respectively. Phage B9 has a genome of 93,641 bp and encodes 167 predicted proteins, of which 29 were identified by mass spectrometry. This phage holds a capsule depolymerase (B9gp69) able to digest extracted exopolysaccharides of both K30 and K45 strains and remains active in a wide range of pH values (5 to 9), ionic strengths (0 to 500 mM), and temperatures (20 to 80°C). B9gp69 was demonstrated to be nontoxic in a cell line model of the human lung and to make the K45 strain fully susceptible to serum killing Contrary to the case with phage, no resistance development was observed by bacteria targeted with the B9gp69. Therefore, capsular depolymerases may represent attractive antimicrobial agents against infections. Currently, phage therapy has revived interest for controlling hard-to-treat bacterial infections. is an emerging Gram-negative pathogen able to cause a variety of nosocomial infections. Additionally, this species is becoming more resistant to several classes of antibiotics. Here we describe the isolation of a novel lytic myophage B9 and its recombinant depolymerase. While the phage can be a promising alternative antibacterial agent, its success in the market will ultimately depend on new regulatory frameworks and general public acceptance. We therefore characterized the phage-encoded depolymerase, which is a natural enzyme that can be more easily managed and used. To our knowledge, the therapeutic potential of phage depolymerase against is still unknown. We show for the first time that the K45 capsule type is an important virulence factor of and that capsule removal via the recombinant depolymerase activity helps the host immune system to combat the bacterial infection.
鲍曼不动杆菌是一种重要的医源性感染病原体,能够迅速对所有已知抗生素(包括黏菌素)产生耐药性。作为一种替代治疗药物,我们分离到一种新型肌病毒(vB_AbaM_B9),它能够特异性感染并裂解 K45 和 K30 荚膜型菌株。噬菌体 B9 的基因组大小为 93641bp,编码 167 个预测蛋白,其中 29 个通过质谱鉴定。该噬菌体携带一种荚膜解聚酶(B9gp69),能够消化提取的 K30 和 K45 菌株的胞外多糖,并且在广泛的 pH 值(5 至 9)、离子强度(0 至 500mM)和温度(20 至 80°C)下保持活性。B9gp69 在人肺细胞系模型中证明是非毒性的,并使 K45 菌株对血清杀伤完全敏感。与噬菌体相反,目标细菌没有观察到对 B9gp69 的耐药性发展。因此,荚膜解聚酶可能是治疗 感染的有吸引力的抗菌药物。目前,噬菌体治疗重新引起了人们对控制难以治疗的细菌感染的兴趣。鲍曼不动杆菌是一种新兴的革兰氏阴性病原体,能够引起多种医院获得性感染。此外,该物种对几类抗生素的耐药性越来越强。在这里,我们描述了一种新型裂解肌噬菌体 B9 的分离及其重组解聚酶。虽然噬菌体可以成为一种有前途的抗菌替代药物,但它在市场上的成功最终将取决于新的监管框架和公众的普遍接受。因此,我们对噬菌体编码的解聚酶进行了特征描述,它是一种天然酶,更容易管理和使用。据我们所知,噬菌体解聚酶针对 的治疗潜力尚不清楚。我们首次表明,K45 荚膜型是 鲍曼不动杆菌的一个重要毒力因子,通过重组解聚酶活性去除荚膜有助于宿主免疫系统对抗细菌感染。